Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS): Initial Launch Experience (P1.372)

Objective: Report initial results from the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) project. Background: The Learning Health System (LHS) concept involves collecting standardized clinical and imaging data during the course of patient care. The data would then serve two purposes simultaneously: data-driven clinical care decisions and systematic learning. Design/Methods: MS PATHS was designed around the LHS concept, through collaborative meetings in 2015–2016. MS PATHS participants self-administer the Multiple Sclerosis Performance Test (MSPT) at routine clinical visits. MSPT is an iPad-based medical device designed and validated for MS. MSPT includes components of the MSFC-4, NeuroQoL, and a standardized MS history. For imaging data, brain MRIs are acquired on 3T Siemens scanners using identical image acquisition parameters, to allow generation of highly standardized MRI-metrics. Participants may also elect to contribute to a biorepository. Results: As of Oct 19, 2016, seven US centers were participating in MS PATHS in collaboration with Biogen, under guidance of a steering committee of 3 neurologists and 1 neuroradiologist from participating centers and a Biogen representative. From May 17, 2016 through October 19, 2016, 1507 patients with MS were enrolled in MS PATHS, 317 with two or more visits. Data from 1127 MSPT assessments are currently available in the LHS database, 342 with brain MRIs. Opt-in rate for data sharing has exceeded 90%, suggesting the study will yield a representative population from participating centers. Across patients currently enrolled (mean+− SD): age=52+/−12 years, Walking Speed Test = 8.46 +/− 5.54 sec, and Dominant Hand Manual Dexterity Test = 28.3 +/− 7.7 sec. Updated results and lessons learned will be presented. Conclusions: MS PATHS is the first LHS established in MS. Enrollment has been rapid, and patient acceptance high. Standardized, comprehensive clinical and imaging data collection will accelerate collaborative research efforts and support data-driven patient management. Study Supported by: Biogen Disclosure: Dr. Bermel has received personal compensation for activities with Biogen, Novartis, Genzyme, Genentech. Dr. Bermel has received research support from Biogen and Genentech. Dr. Mowry has received royalty payments from UpToDate. Dr. Mowry has received research support from Teva Pharmaceuticals, Biogen, and Sun Pharma. Dr. Krupp has received licensing and/or royalty fees from Johnson and Johnson, AbbVie, and Grifols. Dr. Jones has received personal compensation for activities with Siemens as a speaker. Dr. Naismith has received personal compensation for activities with Acorda, Alkermes, Bayer, Biogen, EMD Serono, Genentech, Genyzme, Novartis, and Teva. Dr. Naismith has received research support from Alkermes. Dr. Boster has received personal compensation for activities with Biogen, Mallinckrodt, Medtronic, Novartis, Sanofi Genzyme, and Teva for consulting or non-CME services. Dr. Hyland has nothing to disclose. Dr. Izbudak has received research support from Siemens Medical Solutions and Bayer HealthCare. Dr. Lui has nothing to disclose. Dr. Benzinger has received research support from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly). Dr. Benzinger has also participated in clinical trials sponsored by Avid, Lilly, and Roche. Dr. Hersh has received personal compensation for activities with Genzyme as for speaking and consulting. Dr. Williams has received personal compensation for activities with Biogen as employee. Dr. Williams holds stock and/or stock options in Biogen Idec. Dr. Fisher has received personal compensation for activities with Biogen Idec as an employee. Dr. Fisher has received stock and/or stock options in Biogen Idec. Dr. Goyal has received personal compensation for activities with Biogen Idec. Dr. Relton has received personal compensation for activities with Biogen Idec as an employee. Dr. de Moor has received personal compensation for activities with Biogen as an employee. Dr. Phillips has received personal compensation for activities with Biogen as an employee. Dr. Phillips holds stock in Biogen. Dr. Kieseier holds stock and/or stock options in Biogen. Employed by Biogen Idec,,,,,, Dr. Buzzell has received personal compensation for activities with Biogen as an employee. Dr. Datta has received personal compensation for activities with Biogen as an employee Dr. Rudick has received personal compensation for activities with Biogen Idec. Dr. Rudick holds stock and/or stock options in Biogen Idec.